An overview of breast cancer stages and CDK4/6 inhibitors
Identifying risk of recurrence in early breast cancer
Clinical trial data on CDK4/6 inhibitors in early and advanced breast cancer
Deregulation of the cell cycle is a hallmark of cancer, and research on cell cycle control has allowed identification of potential targets for anticancer treatment. Palbociclib is a selective inhibitor of the cyclin-dependent kinases ...
Selecting CDK4/6 inhibitors in advanced breast cancer
Congress highlights from SABCS 2022, ASCO and ESMO
CDK4/6 inhibitors are a promising new class of drugs for hormone-receptor-positive breast cancer and have been shown to overcome and delay hormone resistance in advanced breast cancer.
Follow three patient case studies in this interactive module
Join the expert faculty in this roundtable
Learn about early breast cancer risk stratification and management